Abstract | The concept that some childhood malignancies arise from postnatally persistent embryonal cells has a long history. Recent research has strengthened the links between driver mutations and embryonal and early postnatal development. This evidence, coupled with much greater detail on the cell of origin and the initial steps in embryonal cancer initiation, has identified important therapeutic targets and provided renewed interest in strategies for the early detection and prevention of childhood cancer.
Human cancer is a multistep process that has inexorably evolved over many years towards genomic instability and life-threatening cellular phenotypes. The recognition that a minority of cancer cells within a tumour possess potent embryonal features or the plasticity to revert to embryonal features during postnatal life has generated the cancer stem cell hypothesis 1 , which reflects the almost limitless heterogeneity that is evident in most tumours. Cancer stem cells are not replicates of their embryonal counterparts but instead have some features of embryonal cells that provide a survival advantage that is suited to a particular time and place during tumour evolution 1 . By contrast, cancers that present very early in a child's life often have embryonal features but must have moved quickly to genomic instability. This rapid evolution might occur when a cancer cell arises directly from an embryonal cell or when a mature prenatal cell acquires embryonal properties that favour survival in the prenatal and postnatal environments. Prenatal tumorigenic mutations might be more likely to occur in stem or progenitorlike cells that have characteristics (such as unrestrained self-renewal) that are essential in utero but that are fatal in postnatal life. Understanding the characteristics of these cells might be important in understanding more about childhood cancer: why it develops, how best to treat it and, potentially, how to prevent it.
For some childhood cancers, such as retinoblastoma, infant acute lymphoblastic leukaemia (ALL) and malignant rhabdoid tumours, there is evidence of an embryonal cell of origin. However, it is unclear whether these embryonal cancers arise from embryonal cells in utero or as a consequence of a single oncogenic event in a more mature prenatal cell with rapid progression to genomic instability; and this model of a single oncogenic event in a mature prenatal cell is likely to be the case for mixed lineage leukaemia (MLL) fusion genes in infant ALL and for SMARCB1 (also known as INI1) mutations in malignant rhabdoid tumours 2, 3 . A unique characteristic of certain childhood cancers, such as Wilms' tumour and neuroblastoma, is a precursor hyperplasia of embryonal cells that presents in infancy but that has an overwhelming tendency to undergo spontaneous regression and cell death 4, 5 . More than 150 years ago, pathologists first suggested that postnatally persistent embryonal remnant cells ('rest cells') lay dormant in normal tissues but retained their capacity for growth and might later undergo malignant transformation [6] [7] [8] . Today, we know that during embryogenesis many more cells are produced than are required for organogenesis. Thus, mechanisms such as trophic factor withdrawal are required for deleting cells that are in excess after organogenesis is complete. In rare instances, as a potential first pathological step towards cancer, some embryonal cells can resist these cell death signals, and they can later acquire additional alterations, which lead to postnatal malignant transformation.
Some types of cancer with embryonal histology, such as germ cell tumours, more commonly arise in early adulthood. However, it is unclear whether these malignancies represent cellular reversion from a mature form to an embryonic form in adult life or postnatal persistence of embryonal cells, because there is no evidence of a 'rest disease' pre-dating these cancers. Therefore, although the concept of rest cells is helpful in considering the processes that might underlie cancer development in young children, lack of evidence for a rest disease before malignant transformation has been taken as evidence that few childhood cancers arise through this mechanism. However, a substantial number of childhood malignancies seem to arise prenatally. If all childhood malignancies with a suspected prenatal cell of origin are grouped together, it is apparent that almost one-half of all childhood cancers might have prenatal origins (TABLE 1) . In B cell-lineage ALL (B-ALL), transient myeloproliferative disorder (TMD) and myeloid leukaemia-Down syndrome (ML-DS), driver mutations and causal gene rearrangements or balanced translocations are detectable in perinatal peripheral blood leukocytes years before clinical presentation, which indicates that these childhood cancers are initiated in utero 9, 10 . Recent studies using genetically altered animal models, family linkage analyses, large-scale expression profiling and genomewide association studies (GWAS) have identified a large number of genes that are possible drivers in prenatal cancers, and many of these genes also have a role in embryonal development. This Opinion article focuses on four childhood malignancies with, we argue, the strongest evidence for a prenatal cell of origin: neuroblastoma, TMD and ML-DS, B-ALL, and medulloblastoma. We discuss their prenatal origins in the context of normal tissue development, the potential cell of origin and the evidence for an embryonal precancer. Although embryonal rest cells are often seen as 'normal' in the context of the rest cell hypothesis, we feel that this definition limits the • Animal modelling with Th-MYCN mice shows rest formation prior to tumour formation owing to resistance to developmental deletion signals 15, 19 • Neural crest stem cell allografts generate neuroblastoma with oncogene (MYCN and ALK
F1174L
) transduction 44 • Young age of incidence (<5 years) 12 • Multifocal or bilateral primary tumours in tissues derived from the embryonic neural crest in <5% of patients 11 • Normal fetal neuroblasts are highly similar to tumour-derived neuroblasts 45 • Failure of complete sympathoadrenal maturation -neuroblast rests and increased levels of catecholamines (a neuroblastoma marker) in subclinical patients 46, 47, 172 • Low-risk neuroblastoma and rest cells frequently regress 4, 46 Wilms' tumour Primitive metanephrogenic blastema Not applicable • Young median age of incidence 173 • Wilms' tumour can be bilateral 173, 174 • Inactivating mutations in kidney development gene WT1 predispose for Wilms' tumour 173 • Nephrogenic rests adjacent to tumours 174 • WT1 + nephrogenic rests found adjacent to WT1 + tumours 174 • Nephrogenic rests can spontaneously regress 5, 175 Medulloblastoma Neural progenitors of the developing cerebellum or brainstem
• Aberrant SHH signalling through development recapitulates SHH subgroup medulloblastoma 114, 121, 122 • SHH subgroup medulloblastoma modelling shows premalignant embryonal cells prior to tumour formation owing to resistance to developmental cell deletion signals 117 • Activating mutations in β-catenin and aberrant WNT signalling in OLIG3 + neural precursors through brainstem development can recapitulate medulloblastoma 137 • Animal modelling shows that cerebellar development genes (MYCN and MYC) can recapitulate medulloblastoma in SHH-independent medulloblastoma [126] [127] [128] • The SHH subtype is associated with the developmental disorder Gorlin syndrome
111
• Allelic loss on chromosome 9 (including the SHH pathway suppressor PTCH1) occurs in 30% of tumours 113 
Retinoblastoma
Retinal progenitors of the developing eye
Inactivation of retinal development genes Rb1 and p107 in retinal progenitors causes prolonged proliferation of progenitors through development and is sufficient to recapitulate retinoblastoma 176, 177 • Familial cases are often bilateral, multifocal and usually occur in the first 2 years of postnatal life 143, 178 • Retinal progenitor cell proliferation occurs only in the fetal retina 178 • Premature baby reported with retinoblastoma in early postnatal life 179 • Patients are defined by familial and sporadic inactivation of the retinal development gene RB1 • Studies of monozygotic twins with concordant leukaemia (ETV6-RUNX1-positive pre-B-ALL and infant ALL) 79, 81 • Studies of neonatal blood spots from twin pairs show clonal evolution in utero of a pre-leukaemic population expressing ETV6-RUNX1 81, 86 • Pre-leukaemic cells detected in neonatal blood spots for most pre-B-ALL patients 2, 82 discussion of the origins of some childhood cancers. In this article, we use a broader term, 'embryonal precancer' , for all premalignant cellular hyperplasia that is detectable in the perinatal period. It is possible that embryonal precancer cells are already on the path towards malignancy but that these cells retain the compulsion to die in the postnatal environment because they still require additional postnatal changes for malignant transformation. The aim of suggesting this term is to facilitate discussion and experimentation that is directed towards identifying common aetiological features, strategies for early diagnosis and therapy, and possibly the prevention of childhood cancers of prenatal origin.
Neuroblastoma
Neuroblastoma is a malignancy of the sympathetic nervous system that almost exclusively occurs in infancy and early childhood 11, 12 . Primary neuroblastoma arises in the adrenal medulla or sympathetic ganglia along the paravertebral axis. Considerable evidence suggests that neuroblastoma is initiated in utero during sympathoadrenal development and that it goes through an embryonal precancer phase.
Candidate neuroblastoma initiation factors linked to sympathoadrenal development. The cells of the mature adrenal medulla and sympathetic ganglia originate in a transient collection of neural crest progenitors that rely on spatially and temporally regulated extrinsic signals for the later steps of migration, specification, divergence and maturation 13 ( FIG. 1) . Sympathoadrenal cells from the neural crest in the trunk region of the embryo follow a ventral migratory pathway from the neural crest and neural tube, and they receive signals from somites, the ventral neural tube, the notochord and the dorsal aorta 13 . During normal sympathoadrenal development, expression of the proto-oncogene MYCN is high in the early post-migratory neural crest, where it regulates the ventral migration and expansion of neural crest cells 14 . MYCN protein levels gradually reduce in differentiating sympathetic neurons [14] [15] [16] , which suggests that sympathoadrenal maturation requires low or absent MYCN expression 14 . Consistent with this finding is the observation that MYCN transduction into quiescent rat sympathetic neurons reactivates cell cycling and blocks cell death that is induced by nerve growth factor (NGF) withdrawal 15, 16 . After sympathoadrenal specification and expansion of the primary sympathetic ganglia, sympathoadrenal precursor development diverges into neuronal or chromaffin cell fates 13 . On the basis of expression patterns of differentiation markers, the earliest cell of origin for neuroblastoma is thought to be a neural crest cell specified to the sympathoadrenal lineage that has not received or responded to cues that determine neuronal or chromaffin cell fate (FIG. 1) . Excess neural precursors undergo apoptotic cell death at the final stage of sympathoadrenal maturation 17 , and this process is catalysed by local NGF deprivation. In zebrafish, persistent MYCN expression in sympathoadrenal precursor cells markedly blocks development towards a chromaffin cell fate and thereby leads to neuroblastoma 18 . Overexpression of human MYCN under the control of the rat tyrosine hydroxylase (Th) promoter in Th-MYCN-transgenic mice is sufficient to recapitulate neuroblast precancer (discussed below in the context of humans) and tumorigenesis 15, 19, 20 . Transformation from precancer to cancer in Th-MYCN mice requires even higher levels of MYCN than are provided by the transgene. This occurs via transgene amplification and feedforward loops between MYCN and increased levels of the NAD-dependent deacetylases sirtuin 1 (SIRT1) and SIRT2, which increase MYCN stability 21, 22 . This cellular tolerance for high levels of MYCN is surprising, as supraphysio logical levels of MYC expression should lead to apoptosis and senescence through the ARF (encoded by CDKN2A)-p53 stress response pathway 23 . Neuroblast precancer cell cultures from perinatal Th-MYCN mouse ganglia have lower basal and induced p53 levels than wildtype ganglia, which in turn have lower p53 levels than those of mature ganglia 19 . When p53 is reactivated in precancer cell cultures, the cells become sensitive to NGF deprivation 19 . Inactivation of the ARF-p53 pathway in neuro blast precancer cells can be accomplished by the Polycomb complex protein BMI1, which functions as a p53 protein E3 ubiquitin ligase in Th-MYCN mice, or by mutant anaplastic lymphoma kinase (ALK), through effects on PI3K and MAPK signalling in zebrafish 19, 24 . These findings indicate that there might be an inherent susceptibility to oncogenic stress in some embryonal cells that lack robust p53 stress responses.
These experiments mechanistically connect MYCN with the maintenance of neuroblast precancer cells and indicate that MYCN is a driver of resistance to developmentallytimed trophic factor withdrawal signals • GATA1 mutation detected in utero 66 • In utero TMD diagnosis; condition present in preterm neonates 53 • Median age of diagnosis is 3-7 days postnatally, range 0-65 days 52, 53 • TMD regresses prior to progression to ML-DS in 25% of patients 49 MRTs 
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Birth at neuroblastoma initiation. The marked downregulation of high affinity nerve growth factor receptor (NTRK1; also known as TRKA) in MYCN-amplified neuroblastoma cells blocks neural differentiation. Conversely, neurotrophic tyrosine kinase receptor type 2 (NTRK2) responds to brain-derived neurotrophic factor (BDNF) which has survivaland growth-promoting actions on neurons. BDNF and NTRK2 are expressed by MYCNexpressing neuroblastoma cells and maintain an autocrine cell survival loop that blocks differentiation and apoptosis 11 . By 5 weeks into human development, the ventrally migrating neural crest cell responds to bone morphogenetic protein signalling from the dorsal aorta to promote a transcriptional programme that specifies the neuronal and catecholaminergic properties of the expanding primary sympathetic ganglia 13, 25, 26 . Murine achaete-scute homologue 1 (MASH1) then promotes paired mesoderm homeobox protein 2A (PHOX2A) expression, which, together with PHOX2B, drives the expression of enzymes for catecholamine biosynthesis. PHOX2B initiates a secondary transcriptional programme, which controls terminal sympathoadrenal differentiation. Heterozygous germline mutations of PHOX2B are associated with a subset of familial neuroblastoma 27, 28 . Neuroblastoma that is driven by PHOX2B mutations often clinically presents in conjunction with the neural crest disorders Hirschsprung disease and congenital hypoventilation syndrome; and this reinforces the connection between neuroblastoma and defective neural crest development. PHOX2B mutant proteins seem to be oncogenic in a dominant-negative manner and they promote inappropriate proliferation in neural precursors 29, 30 . Interestingly, neuroblast precancer cells from Th-MYCN mice have high levels of PHOX2B expression, which indicates a possible indirect downstream link to MYCN 31 . Future experiments should uncover the finer detail of the regulatory relationships between these proteins in development and disease.
Paralogous RNA-binding proteins LIN28A and LIN28B regulate the expression of the let-7 microRNA family during embryogenesis, thereby controlling developmental timing and cell growth during neural crest cell lineage commitment 32 . Targeted expression of LIN28B to the developing neural crest of transgenic mice induces neuroblastoma 33 . LIN28B downregulates let-7 pre-microRNAs, which increases MYCN expression 33 . LIN28B is known to be crucial in the maintenance of stemness throughout embryonic development, and this function might maintain the undifferentiated neuroblast phenotype 33, 34 . It will be important to determine whether Lin28b-transgenic mice recapitulate the neuroblast precancer disease that occurs in Th-MYCN mice. The known role of LIN28B in neurogenesis 35 fits well with a model of neuro blastoma initiation that requires aberrant regulation of developmental proteins. LIN28B can be amplified and highly expressed in some neuroblastoma tumours, which correlates with poor prognosis 33 . Interestingly, LIN28B-let-7 signalling through MYCN seems to be important in another putatively embryonal cancer, germ cell tumour 36 . ALK has a key role in early sympathoadrenal development to protect neuroblast growth in utero against nutrient deprivation 37, 38 . Germline and somatic mutations in ALK that cause constitutive kinase activation are present in 8-10% of neuroblastoma cases and correlate with poor prognosis 39, [40] [41] [42] . The most common and aggressive activating mutation of ALK, which results in F1174L, is sufficient for tumour formation when specifically expressed in the neural crest in transgenic mice 43 and when neural crest cells expressing this mutation are transplanted into nude mice 44 . ALK-F1174L has been associated with MYCN amplification in human tumours, and co-expression of ALK-F1174L and MYCN synergistically promotes tumour formation in vivo, which Under the influence of MYCN and bone morphogenetic proteins (BMPs), neuroblast progenitors migrate from the neural crest and around the neural tube to a region that is immediately lateral to the notochord and dorsal aorta. At this site, the cells undergo specification as the primary sympathetic ganglia (PSG) before divergence into neural cells of the mature sympathetic ganglia or chromaffin cells (not shown). MYCN is a 'first hit' by virtue of the observations from a tyrosine hydroxylase (Th)-MYCN-transgenic mouse model, whereas mutations in anaplastic lymphoma kinase (ALK) and paired-like homeobox 2B (PHOX2B) are germline mutations. Local access to nerve growth factor (NGF) determines whether a normal sympathetic ganglion cell (blue) matures into a terminal ganglion cell or undergoes apoptotic cell death. A relatively common pathological state is postnatal survival of neuroblast precancer cells (purple), which requires the cell that is destined to become malignant to be resistant to trophic factor withdrawal before these persistent precancer cells undergo a third change to induce transformation, which presents as neuroblastoma in early childhood. HAND2, heart and neural crest derivatives expressed 2; MASH1, murine achaete-scute homologue 1. suggests that these may be cooperating events in tumour initiation 43 . Thus, aberrant MYCN expression or function in collaboration with the disordered function of a small group of key neurodevelopmental regulators are good candidates for neuroblast precancer initiation. The exact order of these events and the intrauterine factors that favour neuroblast precancer are unknown.
Neuroblastoma as an embryonal precancer.
Several clinical and experimental features link neuroblastoma to defective embryogenesis and pathological neuroblast precancer. The idea of an embryonal origin for human neuroblastoma is supported by expression profiling showing that human fetal adrenal neuroblasts have gene signatures that are remarkably similar to those of neuroblastomas 45 . In some patients with neuroblastoma, new tumours form at different times and sites early in the child's life, which suggests a 'field' of premalignant lesions, thereby linking tumorigenesis to deregulated development.
A key feature of clinical or experimental embryonal precancer is the compulsion to undergo cell death and spontaneous regression in the postnatal environment, thereby mirroring features of embryonal cells in utero that are not required for organogenesis. The incidence of subclinical neuroblastoma is much higher than the frequency of clinical disease. A small proportion of patients with neuroblastoma present in early infancy with metastatic special disease (previously known as stage 4S neuroblastoma), which undergoes regression without therapy. Autopsies of sympathoadrenal tissues from infants whose diagnosed cause of death was not cancer have shown an incidence of neuroblast precancer that is 40-fold higher than the incidence of the clinical disease 46 . Mass infant-screening programmes in the 1990s for the neuroblastoma tumour marker of catecholamines in urine samples found subclinical tumours at a frequency that was more than twofold higher than the clinical incidence of neuroblastoma 47 . These mass screening programmes aimed to prevent the later incidence of metastatic neuroblastoma by early tumour detection in infancy at the localized stage, followed by surgery, but they were unsuccessful in this regard 47 . One explanation is that neuroblast precancer cells that later progress to metastatic neuroblastoma might already be fundamentally different at birth from the more common spontaneously regressing disease. This hypothesis is suggested on the basis of work using Th-MYCN-transgenic mice.
The work showed that a small number of neuroblast precancer cells that developed into tumours had undergone early MYCN transgene amplification 15 . Moreover, recent transgenic zebrafish models of neuroblastoma also indicate that there is a need for a cooperating signal that inactivates MYCN-induced apoptosis at tumour initiation 18 . Animal models confirm that metastatic neuroblastoma can arise from neuroblast precancer cells 15 . The postnatal period of quiescent neuroblast precancer cells in sympathoadrenal tissues offers a time window during early infancy when alternative forms of screening for precancer might be envisaged on the basis of a germline cancer susceptibility profile and recently described methods of detecting tumour DNA in peripheral blood 48 . Furthermore, it might be expected that drugs that restore the p53 stress response in neuroblast precancer cells, given briefly at this crucial early embryonal precancer phase, might be effective in restoring the capacity for spontaneous regression and thereby preventing malignant transformation.
Another prenatal cancer with an embryonal precancer phase that offers substantial opportunities for early detection and therapy is TMD and ML-DS.
TMD and ML-DS
TMD is a megakaryocyte (MK) lineage disease that clinically presents at birth in 5-10% of children with DS 49, 50 . The clinical abnormalities that are associated with TMD spontaneously resolve in early infancy in almost all affected patients. However, approximately 20% of these children present 2-4-years later with ML-DS, which is an acute MK lineage leukaemia 49, 51 . MK development and TMD pathogenesis. TMD develops in utero during megakaryopoiesis. MK progenitors (MKPs) are first produced from haematopoietic stem cells (HSCs) in the yolk sac, the aorto-gonadmesonephros and thereafter in the fetal liver [52] [53] [54] . Rarely, TMD can occur in infants without DS, but all of these cases have trisomy 21 mosaicism in the bone marrow, and this supports the key role of trisomy 21 in TMD pathogenesis. Moreover, the frequency of conversion to ML-DS is the same for patients with TMD that is linked to DS or non-DS trisomy 21 mosaicism 50, 52, 53, 55 .
Fetal liver haematopoiesis in DS shows specific expansion of HSC and MKP compartments 56, 57 . These trisomy 21-induced changes are likely to occur during definitive haematopoiesis from the yolk sac or the aorto-gonad-mesonephros 56, 57 . Ts65Dn mice carry an extra chromosome, with gene copies of most of mouse chromosome 16, which is orthologous to human chromosome 21 (REF. 58 ). Ts65Dn mice do not spontaneously develop TMD, but they display abnormal megakaryopoiesis and chronic myelofibrosis 58 . MK development and differentiation is controlled by combinations of cytokines and other mediators that are present within a haematopoietic vascular and endosteal niche 57, 59 . Of the genes on chromosome 21, several are good candidates for leukaemogenesis: runt-related transcription factor 1 (RUNX1; also known as AML1), ERG, ETS2, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1Α) and GA binding protein transcription factor-α (GABPA). RUNX1 expression is not increased in ML-DS 60 , and trisomy of Runx1 was not required for the development
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Adaptive B2 cells B2 cells that are responsible for the production of antibodies during adaptive immunity.
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Bilaterally paired blocks of mesoderm that form along the anterior-posterior axis of the developing embryo. . The GATA1 gene is mutated in megakaryoblasts in all cases of TMD and ML-DS, and these mutations, which occur in exon 2 or at the exon 2-intron boundary of GATA1, lead to exclusive production of truncated GATA1, termed GATA1s 65 , as early as 21 weeks of gestation 66 . GATA1s does not have an amino-terminal transactivation domain, but it retains both DNA-binding zinc fingers, and its expression leads to the impairment of GATA1-mediated regulation of other transcription factors, including GATA2, IKAROS family zinc finger 1 (IKZF1), MYB and MYC in fetal MKs 67 . Paired sample analysis by several groups indicates that the same GATA1 mutation is present in TMD and matched ML-DS samples 53, [68] [69] [70] . However, neither the mutation site nor the nature of the mutation in GATA1 exon 2 predicts progression to ML-DS 70 and, surprisingly, Kanezaki et al. 71 found an association between low levels of GATA1s protein and a higher probability of progression to ML-DS.
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TMD as an embryonal precancer. TMD develops in utero when blood cell production resides in the fetal liver 52, 53, 72, 73 . Trisomy 21 creates MKP hyperplasia, and increased MK and erythrocyte progenitor (MEP) clonogenicity, which precedes GATA1s expression 54, 56, 74 . Elegant mouse studies of the effects of a GATA1s-knock-in allele showed that GATA1s expression leads to the transient hyperproliferation of an embryonic MKP that begins in the yolk sac, then moves to the fetal liver and ultimately disappears once haematopoiesis moves to the bone marrow postnatally 67 . Fetal liver-derived megakaryoblasts have been recently shown to differ from their adult counterparts by their low type 1 interferon production: type 1 interferons are known inhibitors of MKPs. This might help to explain why trisomy 21 and GATA1s have specific effects on fetal MKPs 75 , and it also indicates that exogenous interferon-α might be an effective deletion therapy for residual fetal MKPs in TMD.
Thus, to date, the evidence indicates that the progression from normal prenatal MKP to TMD requires trisomy 21 as the 'first hit' (REF. 49 ) and then somatic GATA1 mutation as the 'second hit' . We think that it is likely that trisomy 21 and GATA1s combine to promote TMD as an embryonal precancer in some children with DS by causing inappropriate MKP hyperplasia in the fetal liver. Like other embryonal precancers, the MKP cells of TMD retain the compulsion to die in the perinatal period by as yet unknown mechanisms once haematopoiesis shifts to the bone marrow. At birth, TMD cells need a 'third hit' to sustain viability in the face of death signals.
Whether these death signals also involve p53 is unknown. Transcription profiling studies of TMD and ML-DS samples indicate that driver mutations that activate WNT, Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and MAPK-PI3K signalling are good candidates for a 'third hit' (REF. 76) (FIG. 2) . Furthermore, recent xenograft analyses using samples from patients with TMD show distinct subclones emerging on serial transplantation with genomic features of ML-DS, such as chromosome 16q deletion and chromosome 1q gain, which were present at low frequencies in the initial TMD sample 77 . These observations are reminiscent of the process of clonal selection for transgene amplification that occurs in Th-MYCNtransgenic mouse neuroblast precancer cells 15 , and they support the idea that, even at birth, rare leukaemogenic or tumorigenic subclones are present among apparently regressing embryonal precancer cell populations.
Collectively, we think that these data suggest that embryonal precancer cells are not normal embryonal cells that have simply persisted postnatally. Instead, postnatal embryonal precancer cells, like cancer stem cells, have retained embryonal features at the early stages of a traditional pathway towards tumorigenesis. Recent studies using nextgeneration sequencing of peripheral blood DNA from neonates with DS to look for GATA1 mutations indicate that the incidence of TMD could be around 30% 78 . These findings suggest a strategy of predictive testing for TMD in neonates with DS and pave the way for therapeutic intervention studies of TMD as a method of leukaemia prevention.
Another childhood cancer in which leukaemia marker genes have been identified in the perinatal period, suggesting prenatal origins, is B-ALL. However, the absence of a clinical embryonal precancer phase before B-ALL and the rarity of the premalignant clone in the perinatal period means that the application of preventive disease strategies for B-ALL will be more difficult.
B-ALL
ALL is the most common childhood malignancy and arises in B-lineage or T-lineage lymphocyte progenitor cells. We confine our discussion to the more common B-ALL and B cell development, because T-ALL generally presents in adolescence and most of the evidence for a prenatal origin of ALL has been obtained using samples from children with B-ALL.
Leukaemogenesis begins prenatally in children with B-ALL. Leukaemic cells from identical twin pairs with concordant B-ALL share unique, clonal, non-constitutive
Figure 2 | TMD and ML-DS. Children with Down syndrome (DS) can develop a transient myeloproliferative disorder (TMD) at birth, which can later transform to myeloid leukaemia (ML-DS). The production of megakaryocyte and erythrocyte progenitors (MEPs) is increased in the fetal liver of children with DS and trisomy 21 as a 'first hit'. Some megakaryocyte precursor cells develop a 'second hit' mutation in GATA1, which results in a mutant, truncated protein, GATA1s. All children with TMD and ML-DS have GATA1s and more than two copies of chromosome 21. TMD resolves clinically in almost all patients but will later present as ML-DS in 25% of TMD cases. Thus, some TMD cells at birth must survive through unique death resistance mechanisms and might undergo further changes, which lead to genomic instability and clinical presentation as ML-DS. • ETV6-RUNX1
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chromosome rearrangements, even when diagnosed years apart, which indicates that leukaemogenic molecular alterations occur in utero 79, 80 . Further support for the idea of a prenatal origin came from a study of 5-year-old monozygotic twins that aimed to identify leukaemogenic markers 81 . These patients presented with B-ALL and concordant translocation of ETS variant 6 (ETV6; also known as TEL) and RUNX1 genes (ETV6-RUNX1). The leukaemic cells also showed distinct immunoglobulin heavy chain (IgH) and immunoglobulin-κ deleting element (IgK-Kde) gene rearrangements in neonatal blood spot DNA, which indicates that separate pre-leukaemic clones must have evolved before birth 81 . Using IgH rearrangement as a marker for leukaemic clones, several groups have now shown that pre-leukaemic cells can be detected in the neonatal blood spot of most childhood patients with B-ALL, which indicates that the leukaemogenic process begins in utero 2, 82 (FIG. 3) .
The ETV6-RUNX1 fusion gene is a clonal feature of B-ALL cells at diagnosis in more than 20% of patients, but the analyses of neonatal blood spots indicates that it is present at a much higher frequency than the incidence of B-ALL in childhood [83] [84] [85] . Studies of monochorionic ETV6-RUNX1-positive twin pairs (one pre-leukaemic and one leukaemic) have established that the presence of ETV6-RUNX1 in B cells is sufficient to generate a population of pre-leukaemic cells and function as a first hit mutation that results in altered self-renewal and survival properties 86 . However, low ETV6-RUNX1 expression levels are only tolerated by pro-B cells, because these cells terminally differentiate in the long term 87 . Although ETV6-RUNX1 has been found in peripheral blood leukocyte DNA from healthy adults (0.5-8.8%), it is much more frequent in young adults 83 , and this presumably represents pre-leukaemic clones that originated prenatally. ETV6-RUNX1 expression is, of course, not part of the normal B cell developmental programme. Thus, ETV6-RUNX1 operates as a weak oncogenic event in prenatal HSCs or precursor B cells to generate a pre-leukaemic state that, like precancerous neuroblasts and megakaryoblasts, has a short lifespan in the postnatal environment. ETV6-RUNX1 may function as an oncogene only in neonates owing to specific characteristics of fetal B cells
, thereby linking ETV6-RUNX1-initiated leukaemia to the embryonal environment. Overexpression of the erythropoietin receptor early B cell factor 1 (EBF1) and deregulated transforming growth factor-β responses might have a role in the survival of ETV6-RUNX1-initiated pre-leukaemic cells [88] [89] [90] . Both the BCR-ABL1 and MLL-ENL (also known as MLLT1) fusion genes can occur prenatally and might initiate B-ALL 91, 92 . However, the preleukaemic clone also remains clinically silent in the absence of additional changes, such as an IKZF1 mutation 91 . We hypothesize that B-ALL might also follow a traditional tumorigenic pathway that begins in prenatal, partially transformed cells that have adopted characteristics favoured by the embryonal environment but not the postnatal environment. B-ALL might also be preceded by clonal hyperplasia of a small population of transient B cells that, like neuro blast and MK precancer cells, are destined to die unless further changes accelerate the path towards malignancy. A more detailed analysis of genetically modified animal models of B-ALL for lymphoid hyperplasia and its spontaneous regression would diagnosis of B-ALL and thus represent the 'first hit', as they have also been identified in blood samples at birth from children who later developed B-ALL. We hypothesize that, like other types of embryonal precancer cells, many of these partially transformed B-precursor cells die in the perinatal period, while a small number only survive because of a 'second hit' that leads to death resistance. As the incidence of the ETV6-RUNX1 fusion gene is much higher than the clinical incidence of B-ALL, some B-ALL precancer cells must survive the perinatal period to undergo a 'third hit' that leads to clinical presentation. CDKN2, cyclin-dependent kinase inhibitor 2; EBF1, early B cell factor 1; FLT3, FMS-like tyrosine kinase 3; FOXO1, forkhead box O1; IKZF1, IKAROS family zinc finger 1; IL-7, interleukin-7; PAX5, paired box 5; PBX1, pre-B cell leukaemia homeobox 1.
strengthen the hypothesis that B-ALL begins as an embryonal precancer. In this regard, the recent description of mutant TP53 as another familial B-ALL predisposition gene suggests that the p53 stress response might be defective in B-ALL precancer cells -much like neuroblasts from the Th-MYCN mice 15, 19, 93, 94 . However, several important facts are not known for the prenatal phase of B-ALL: the exact embryonal timing and tissue of initiation, and the leukaemogenic order and relative interdependency of the candidate initiator mutations with B cell homeostasis in the prenatal environment. The susceptibility of fetal B cells to the weak ETV6-RUNX1 oncoprotein might be due to the different cell-intrinsic responses of HSCs or innate B1 precursor cells or due to the cell-extrinsic susceptibilities of the fetal liver compared with the postnatal bone marrow
Considerable evidence from mouse models suggests that medulloblastoma passes through an embryonal precancer phase. However, like B-ALL, there is no clinical presentation of a precancer in patients who develop this brain tumour.
Medulloblastoma
Medulloblastoma arises from the developing cerebellum and adjoining structures, and it is the most common malignant brain tumour of childhood. It represents four distinct disease entities: the sonic hedgehog (SHH) and WNT subgroups are named on the basis of the predominant signalling pathway that drives tumorigenesis, whereas group 3 and group 4 medulloblastomas show a more pleiotropic aetiology and do not have an easily identifiable oncogenic driver pathway (FIG. 4) .
Cerebellar development and medulloblastoma tumorigenesis. The fully developed cerebellum comprises an outer cell-sparse cortical layer (molecular layer), a Purkinje cell layer (PCL) and an internal granular layer (IGL). The IGL is comprised of cerebellar granule cells that form excitatory connections with Purkinje neurons 95 . Developmentally, the cerebellar anlage arises from the dorsal part of the anterior hindbrain, which is anteriorly and posteriorly delineated by expression of the homeobox proteins orthodenticle homologue 2 (OTX2) and HOXA2, respectively 96, 97 . OTX2 is a candidate driver for some group 3 medullo blastomas, as it is amplified in 20% of these tumours and frequently overexpressed in SHH-independent subgroups 98 . Expression of OTX2 is abundant in the developing brain and silenced in the adult brain. OTX2 has recently been shown to repress differentiation in medulloblastoma cells, which suggests that amplification of OTX2 could generate embryonal precancer 99 . The observation that OTX2 also drives proliferation and can upregulate MYC suggests that OTX2 might also be important in transforming precancer into medulloblastoma 98, 100 . The first germinal centre of the developing cerebellum initiates along the fourth ventricle in the dorsomedial ventricular zone and gives rise to Purkinje cells, as well as several other types of cerebellar interneurons 101 . Neural tube closure forms the rhombic lip, the anterior portion of which provides a second germinal zone of rapidly proliferating cells that express radial glial markers and gives rise to MATH1 (also known as protein atonal homologue 1)-positive granule cell progenitors (GCPs) 102, 103 . From 24 to 40 weeks of gestation in humans, the volume of the developing cerebellum enlarges fivefold, which corresponds to a >30-fold increase in cerebellar cortex surface area 104, 105 . This expansion is mostly imparted by the rapid proliferation of GCPs, which give rise to cerebellar granule cells and almost all cerebellar cortical neurons 101, 106 . Proliferation of these neuronal progenitors depends on SHH that is produced by Purkinje neurons: inhibiting SHH signalling blocks the proliferation and migration of GCPs 107 . GCPs rostrally migrate along the surface of the developing cerebellum to form the external granular layer (EGL), where they continue to divide and eventually migrate inwards to form the IGL, with consequent depletion of the EGL 108, 109 . This process of GCP maturation
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Haemogenic endothelium from the mouse embryonic day 9 (E9) yolk sac and the para-aortic splanchnopleura independently give rise to the first B progenitor cells that preferentially differentiate into innate B1 cells and marginal zone B cells, but not into adaptive B2 cells
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. Thereafter, B cells are generated from haematopoietic stem cells (HSCs) in the fetal liver until B cell generation is shifted to the bone marrow from birth onwards. Fetal liver-derived B cells show some descriptive and functional differences from bone marrow-derived B cells, such as low terminal deoxynucleotidyl transferase expression and a restricted diversity of the immunoglobulin heavy chain variable and hinge region repertoire 151 . HSCs that are isolated from fetal liver can differentiate into B1 and B2 cells, however, B1 cell production is predominant until the bone marrow takes over and the B2 cell postnatal programme is established 152 . In embryonal or adult haematopoietic tissues, HSCs differentiate into lymphoid-primed multipotent progenitors (LMPPs), which express high levels of FMS-like tyrosine kinase 3 (FLT3), lose megakaryocyte and erythrocyte progenitor (MEP) potential and retain the capacity to differentiate into lymphoid and myeloid cells 153 . LMPPs can differentiate into early lymphoid progenitors, which are the precursors of bone marrow-derived common lymphoid progenitors (CLPs), which give rise to pre-pro-B cells that express B cell lineage-associated genes 154, 155 . Mice that are deficient in FLT3 ligand have reduced CLP levels, whereas mice that are deficient in Flt3 and interleukin-7 receptor (Il7r) do not develop B cells 156, 157 . A plethora of studies has revealed structural rearrangements, deletions, amplifications and point mutations in genes that encode regulators of B lymphocyte development in samples from patients with B-lineage acute lymphoblastic leukaemia (B-ALL), and many of these regulators are candidates for leukaemia initiation; many are transcription factors that regulate B cell development 158 . IKAROS family zinc finger 1 (Ikzf1)-deficient HSCs in mice have a reduced expression of IL-7R and FLT3, and the numbers of LMPPs are reduced; and reduced expression of IKZF1 in mice results in impaired transition from the pro-B cells to pre-B cells. Ikzf1 −/− mice completely lack B cells [159] [160] [161] . IKZF1 is deleted in most BCR-ABL1-positive B-ALL cells, and mice that express mutant IKZF1 develop ALL 162 . Conditional deletion of paired box 5 (Pax5) in mature B cells leads to dedifferentiation towards uncommitted HSCs 163 . Somatic deletion, mutation or rearrangement of PAX5 is detectable in more than 30% of children with B-ALL 164 . PAX5 DNA-binding and internal deletion mutants function as hypomorphic alleles with weak competitive activity 164 . Hypomorphic PAX5 mutations have recently been described in studies of two affected families with inherited B-ALL, thereby representing familial B-ALL predisposition genes 165 . E2A, which encodes the E protein transcriptional regulators E12 and E47, activates the expression of forkhead box O1 (FOXO1) and is required for CLP formation and B lineage specification [166] [167] [168] . Early B cell factor 1 (EBF1) is necessary for pre-pro-B cells to transit to the pro-B stage 169 . Forced overexpression of EBF1 in both wild-type and E2A-deficient HSCs leads to B cell differentiation 170 . Runt-related transcription factor 1 (RUNX1) is indispensable for generating CLPs 171 , and the expression of PAX5, E12, E47 and EBF1 is reduced in B cell precursors that lack RUNX1 (REF. 170 ). Runx1 deficiency in mice leads to a severe reduction in CLPs and to a myeloproliferative phenotype 171 . Nature Reviews | Cancer The connection between SHH signalling and medulloblastoma was initially made in the context of Gorlin syndrome, which is an autosomal dominant disorder that causes developmental defects and predisposes individuals to several cancers, including medulloblastoma 111 . Fine mapping showed the putative gene to be highly homologous to the Drosophila gene Patched (ptc; known as PTCH1 in humans) 112 . Loss of chromosome 9q, which contains PTCH1, occurs in ~30% of all tumours of the SHH subgroup 113 . The PTCH1 protein is an essential negative regulator of SHH signalling; thus, mice that are heterozygous for Ptch1 develop cerebellar medulloblastoma 114 . Other germline mutations that predispose children to SHH medulloblastoma occur because of loss-of-function mutation in Suppressor of fused homologue (SUFU), which is a negative regulator of the SHH signalling 115 . Amplification of GLI family zinc finger 2 (GLI2), which is a positive regulator of the SHH signal, is also implicated in medulloblastoma development 116 . In a mouse model of SHH-induced medulloblastoma, tumour formation was preceded by GCP hyperplasia in the first week of life, which regressed before later emerging as a malignant tumour 117 , in a manner similar to neuroblast hyperplasia in the Th-MYCN mice 15 . However, in vivo labelling studies that follow a precancer to cancer transformation have not yet been carried out in either model. In vitro, the murine GCPs were resistant to SHH withdrawal, and this feature was partially MYCN-dependent 117 . Neural stem cells (NSCs) and GCPs have repeatedly been shown to be the cell of origin for SHH medulloblastoma [118] [119] [120] [121] [122] . MYCN and its homologue MYC have crucial roles in all medulloblastoma subgroups. Brain-specific germline deletion of mouse Mycn results in cerebellar dysplasia 123 . Expression of MYCN is essential for SHH medulloblastoma in mouse models 124 , and amplification of MYCN marks a subset of poor-outcome SHH-driven human tumours 125 . Moreover, tumorigenic SHH signalling markedly increases MYCN expression in GCPs because of effects on MYCN protein stability 117 . MYCN is also expressed in WNT-subgroup and group 4 tumours, with targeted expression of MYCN or MYC driving SHH-independent medulloblastoma in transgenic mice [126] [127] [128] . Group 3 tumours express MYC and have amplification of MYC rather than MYCN 129 .
Thus, there are many similarities between the role of MYCN in generating neuroblast hyperplasia in neuroblastoma and the role of MYCN in generating GCP hyperplasia in medulloblastoma.
WNT signalling has many roles in neural development, and aberrant WNT signalling in NSCs of the cerebellar ventricular zone induces transient proliferation and impaired differentiation 130 . Individuals with familiar adenomatous polyposis (FAP) and WNT pathway-driven colorectal cancer also have an increased risk of developing medulloblastoma 131 . Mutations that increase WNT signalling in members of the WNT signalling pathway have been described in sporadic medulloblastomas [132] [133] [134] . Recent data from the Medulloblastoma Advanced Genomics International Consortium showed that β-catenin (encoded by CTNNB1) displayed canonical exon 3 deletion in most (70-80%) WNT-subgroup medulloblastomas 116, 133, 135 . Insight into the cell of origin for WNTsubgroup medulloblastomas comes from two mouse models, both of which involve the conditional expression of degradationresistant β-catenin under the control of ) to 83%, which suggests that activation of β-catenin and WNT signalling alone are only weak oncogenic events 136, 137 . These MYC-driven medulloblastomas were evident in young mice and were formed from BLBP + oligodendrocyte transcription factor 3-positive (OLIG3 + ) mossy-fibre neuron precursors that are present in the brainstem between embryonic day 11.5 (E11.5) and E15.5, which is consistent with the radiological observation that WNT medulloblastomas are frequently located within the fourth ventricle and infiltrate the dorsal surface of the brainstem 126, 137, 138 . This observation was consistent with the model of OLIG3
+ neural precursors representing a brain stem precancer preceding WNT medulloblastoma.
The pathogenesis of group 3 and group 4 medulloblastoma is less clear, although these groups account for more than 60% of all medulloblastoma cases 139 . Targeted inducible expression of MYCN to the postnatal cerebellum using the glial high affinity glutamate transporter (Glt1; also known as Slc1a2) promoter (Glt1−tTA;TRE−MYCN− Luc; also known as GTML mice) leads to tumours with a transcriptional profile of group 3 medulloblastoma 126 . GTML mice had a normal EGL, which suggests that group 3 medulloblastoma can originate from a cellular population that is distinct from SHH-subgroup medulloblastoma. However, proliferating GCPs that are isolated from cyclin-dependent kinase inhibitor 2C (Cdkn2c)
, Math1-green fluorescent protein (GFP) mice generate group 3 medulloblastoma when transformed with MYC but not MYCN 127 . Furthermore, group 3 tumours have been modelled through MYC transformation of postnatal cerebellar stem cells marked by the expression of prominin 1 (also known as CD133) and the lack of neuronal or glial markers 128 . Thus, it seems that a single oncogene can give rise to multiple different medulloblastoma tumour subtypes, depending on the developmental age and anatomical origin of the transformed cell, and this indicates that susceptibility to medulloblastoma is highly dependent on the embryonal site and stage 140 .
Unifying features of prenatal cancers
The work of Bishop and Varmus 141 defined the forces that drive human cancer as aberrations of our normal adult self 142 . Embryonal cancer initiation seems to be an aberration of our prenatal self. Here, we propose a new definition of embryonal precancer cells that includes all cancers with a prenatal origin, whether they arise directly from an embryonal cell or from a more mature prenatal cell that has acquired pathological properties that favour survival in the postnatal environment. Using this new definition, neuroblastoma and TMD seems to initiate prenatally in cells that display resistance to cell death, numerical excess and differentiation arrest at a stage of tissue ontogeny that is several steps distal to the earliest progenitor cell for each organ (FIG. 5) . We hypothesize that B-ALL cells might also pass through this phase during their evolution towards the clearly malignant state. Mouse models suggest similar features exist for some medulloblastoma subtypes. Indeed, much of the direct evidence for an embryonal precancer phase for these four malignancies comes from mouse models. Thus, these findings raise interesting questions but do not definitively indicate that the same pathways operate in humans. We propose that these precancer cells are groups of abnormal embryonal cells that have undergone changes that allow them to persist in the face of cell deletion signals in the postnatal environment, but they retain the capacity for self-destruction in the postnatal milieu unless other tumorigenic factors intervene to cause genomic instability -a feature that might offer an opportunity for embryonal precancer deletion therapy. Neuroblastoma and TMD modelling indicates that all embryonal precancer cells are not equal at birth, with only a small number undergoing transformation after later exposure to unidentified postnatal environmental influences 15, 77 . The properties that permit some embryonal precancer cells to remain dormant after birth while adjacent cells are dying is currently unknown.
For neuroblastoma and medulloblastoma, the timing and location of the embryonal precancer in utero coincides with a point in the tissue-specific maturation pathway when rapid cell expansion is required, and this is quickly followed by an orderly transition to a terminally differentiated state. Substantial cell death must occur during the final shaping of the nervous system. It is resistance to these death cues that must accompany an inappropriate replication stimulus, such as continued or high levels of MYCN expression. We postulate that individual variation in factors that are required to negatively regulate MYCN expression in specific tissues during embryogenesis; to activate the apoptosis or senescence response to aberrant MYCN expression; or to activate death responses that are imposed by trophic factor withdrawal might explain individual susceptibility to embryonal precancer.
From early in embryogenesis, haematopoietic precursors are in a continual state of replication and self-renewal, in contrast to terminally differentiated sympathetic ganglia and cerebellar neurons. Thus, although both TMD and B-ALL might not arise directly from an embryonal cell, the initial steps in each pathway towards postnatal malignancy involve progenitor cells acquiring characteristics that are favoured in the prenatal development. For TMD (and possibly B-ALL), the timing of precancer initiation coincides with a unique predominance of fetal liver haematopoiesis. In the case of TMD, low interferon responses might be permissive for the survival of trisomy 21-primed and GATA1s mutant MKPs in the normally nonpermissive environment of the bone marrow that exists beyond the perinatal period 75 . The precancer to cancer transition occurs in early childhood, which indicates that some precancer cells must have the capacity for rapid progression towards genomic instability. One explanation for the speed of this process is inherited germline loss-of-function mutation in one allele of a tumour suppressor gene 143 . Another recently proposed mechanism is chromothripsis, whereby a single catastrophic event can lead to massive genomic rearrangement that affects more than one chromosome, rather than the incremental acquisition of single oncogenic mutations over decades [144] [145] [146] . Additional factors that might accelerate the progression from precancer to cancer are several recently described feedforward loops that increase We propose that each of the four embryonal malignancies with evidence of a prenatal origin (neuroblastoma, myeloid leukaemia-Down syndrome, B-lineage acute lymphoblastic leukaemia and medulloblastoma) shares common features: a prenatal proliferative excess in the tissue of origin, a cell-intrinsic mechanism for surviving the hostile early postnatal environment and an accelerated pathway towards genomic instability.
the expression of MYCN to very high levels through the effects of SIRT1, SIRT2 and aurora kinase A on MYCN protein stability 21, 22, 147 . We propose that additional factors favouring rapid malignant transformation of precancer cells are those properties of growth and self-renewal that are inherent in some embryonal cells.
Although chemotherapy, surgery and radiotherapy have improved the cure rates for childhood cancer, this has come at a substantial cost in terms of the severe acute and long-term side effects of therapy, as well as considerable consumption of the paediatric health economy. Early evidence from screening trials in children at increased risk of cancer development owing to germline p53 mutations has revived interest in strategies for the prevention of childhood cancer 148, 149 . Although the early detection of neuroblastoma using increased urine catecholamines failed to detect all neuroblastoma, we envisage greater success when genomic susceptibility markers are incorporated into predictive algorithms for embryonal pre cancer. Therapy that aims to transiently restore p53-mediated or interferon-mediated cell death responses or to block MYCN, ALK, PI3K or MAPK signals in embryonal precancer cells is an exciting strategy for childhood cancer prevention, which must first be demonstrated to be effective in mouse models of embryonal cancer. It is apparent that, with current models and a clearer understanding of the prenatal missteps that initiate embryonal precancer, these novel strategies can be contemplated for the first time.
